Sihe Zhang | Medicine | Distinguished Scientist Award

Distinguished Scientist Award

Sihe Zhang
Nankai University, China

Sihe Zhang
Affiliation Nankai University
Country China
Scopus ID 7409373738
Documents 55
Citations 1,269
h-index 16
Subject Area Medicine
Event Scientific World Research Awards
ORCID 0000-0002-8923-1993

The Distinguished Scientist Award recognizes the scholarly achievements of Sihe Zhang, Professor and Director at Nankai University School of Medicine. His research focuses on cancer biology, drug delivery systems, endocytosis, extracellular vesicles, antibody therapeutics, and translational medicine. Through sustained contributions to hepatocellular carcinoma and ovarian cancer research, he has developed innovative approaches that connect molecular mechanisms with therapeutic applications.[1]

Abstract

Sihe Zhang is a biomedical researcher whose work spans cancer biology, antibody engineering, cellular uptake mechanisms, extracellular vesicle biology, and targeted therapeutic delivery. His investigations have contributed to understanding macropinocytosis, endocytic recycling, tumor progression, and resistance mechanisms in hepatocellular and ovarian cancers. He has also participated in the development of innovative antibody-based therapies and nanomedicine strategies aimed at improving treatment specificity and efficacy. His publication portfolio demonstrates a sustained commitment to translational medical research and interdisciplinary collaboration, supporting advancements in cancer diagnosis, drug delivery, and precision medicine.[1][2]

Keywords

Cancer Biology; Drug Delivery; Endocytosis; Extracellular Vesicles; Antibody Therapeutics; Hepatocellular Carcinoma; Ovarian Cancer; Nanomedicine.

Introduction

Professor Zhang has held academic positions at Nankai University and previously at the Fourth Military Medical University. His career reflects long-term engagement with molecular medicine and cell biology, emphasizing mechanisms that influence cancer progression and treatment response.[1]

Research Profile

His research profile combines laboratory discovery with translational applications. Major themes include cellular trafficking, therapeutic antibodies, tumor microenvironment studies, and targeted delivery platforms designed to improve treatment outcomes in oncology.[1]

Research Contributions

Notable contributions include investigations into CD147-mediated signaling, extracellular vesicle uptake, macropinocytosis-driven drug resistance, and antibody-based cancer therapies. These studies have expanded understanding of tumor biology and therapeutic targeting strategies.[2][3]

Publications

His scholarly record includes 55 indexed publications. Representative works address hepatocellular carcinoma resistance mechanisms, extracellular vesicle biology, peptide delivery systems, anti-CD147 therapeutics, and nanobiotechnology-based treatment approaches.[2][4]

Research Impact

With 1,269 citations and an h-index of 16, his research has influenced studies in cancer therapeutics, molecular oncology, and biomedical engineering. The impact of his work is reflected through citations, collaborations, and peer-review activities across leading journals.[1]

Award Suitability

The breadth of Professor Zhang’s contributions, combined with sustained publication output and translational relevance, aligns with the objectives of the Scientific World Research Awards. His work demonstrates scientific rigor and practical relevance in medicine.[1]

Conclusion

Sihe Zhang has established a recognized research portfolio in cancer biology and therapeutic innovation. His scholarly achievements and ongoing contributions support recognition through the Distinguished Scientist Award.[1]

References

  1. ORCID. (2026). Sihe Zhang (0000-0002-8923-1993) Research Profile.https://orcid.org/0000-0002-8923-1993
  2. Qian, L., et al. (2025). The uptake of extracellular vesicles: Research progress in cancer drug resistance and beyond. Drug Resistance Updates.https://doi.org/10.1016/j.drup.2025.101209
  3. Qi, F.Z., et al. (2024). Hypoxia-activated ADCC-enhanced humanized anti-CD147 antibody. MedComm.https://doi.org/10.1002/mco2.512
  4. Sun, Z., et al. (2023). Cell-Penetrating Peptide-Based Delivery of Macromolecular Drugs. Biomedicines.https://doi.org/10.3390/biomedicines11071971
  5. Wang, B., et al. (2024). Hypoxia-activated selectivity-improved anti-PKM2 antibody combined with prodrug TH-302. International Journal of Biological Sciences.https://doi.org/10.7150/ijbs.92211

Jacek Kotuła | Medicine | Research Excellence Award

Assist. Prof. Dr. Jacek Kotuła | Medicine | Research Excellence Award

Doctor | University of Wrocław | Poland

Assist. Prof. Dr. Jacek Kotuła, affiliated with Wrocław Medical University, is a researcher in orthodontics, dentistry, and medical ethics. His research interests include cephalometric analysis, bone remodeling, and orthodontic biomechanics. He has strong skills in CBCT imaging, finite element modeling, and clinical research. With impactful publications in medical journals, he has gained academic recognition. According to Google Scholar, he has 230 citations, an h-index of 9, and an i10-index of 8, reflecting his contributions to modern orthodontic science.

 

Citation Metrics (Google Scholar)

230
150
100
50
0

Citations

230

i10-index

8

h-index

9

Citations

i10-index

h-index

View Google Scholar Profile

Featured Publications

 

Shahin Zandieh | Medicine | Innovative Research Award

Prof. Dr. Shahin Zandieh | Medicine | Innovative Research Award

Professor | Hanusch-Krankenhaus | Austria

Prof. Dr. Shahin Zandieh is a medical imaging and diagnostic radiology specialist whose research spans musculoskeletal biomechanics, cardiovascular imaging, oncologic radiology, and advanced radiomics. With 49 publications, over 550 citations, and an h-index of 12, his scientific work reflects a strong interdisciplinary approach to clinical diagnosis, disease characterization, and imaging-guided evaluation of structural abnormalities. His contributions extend across orthopedic, cardiovascular, endocrine, and oncological systems through innovative use of MRI, CT, X-ray, and radiomic feature extraction.A notable component of Prof. Dr. Zandieh’s research focuses on orthopedic imaging and biomechanical assessment, including comparative studies such as the analysis of proximal chevron osteotomy versus Lapidus arthrodesis in managing hallux valgus deformities. His work provides clinically meaningful insights for surgeons, improving treatment selection, operative planning, and postoperative evaluation.In the field of cardiovascular imaging, he has explored rare cardiac pathologies such as “toothpaste tumor” manifestations of the mitral valve, enhancing the diagnostic awareness of uncommon presentations through multimodal radiologic evaluation. His studies also extend to endocrine-related morphologic changes, such as MRI-based radiomics used to detect cardiac variations influenced by autoimmune thyroid disorders—paving the way for AI-assisted diagnostic tools.Prof. Dr. Zandieh has also contributed to oncologic radiology, documenting rare metastatic patterns including giant ovarian metastasis from breast cancer. These case-based investigations broaden clinician understanding of atypical disease progression.Collectively, his research strengthens clinical imaging practice by integrating radiomics, rare-case documentation, biomechanics, and cross-system diagnostic strategies—advancing precision diagnosis, personalized treatment planning, and the broader field of radiological science.

Profiles: Scopus |ResearchGate

Featured Publications

Fezoulidis, N., Slavicek, J., Nonninger, J.-N., … , & Zandieh, S. (2025). Quantitative CT perfusion and radiomics reveal complementary markers of treatment response in HCC patients undergoing TACE.

Behanova, M., Sokhan, A., Haschka, J., … , & Kocijan, R. (2025). AI-supported opportunistic detection of vertebral fractures on routine CT scans: Diagnostic performance and clinical relevance.

Al-Taiee, B., Lamiss, M., Slavicek, J., … , & Zandieh, S. (2025). Disseminated miliary tuberculosis following intravesical BCG therapy: A rare but serious complication.

Kainz, B., Hergan, K., & Zandieh, S. (2025). Große Ovarialmetastase beim Mammakarzinom: Ein seltener Fall.

Prof. Dr. Shahin Zandieh’s work advances medical imaging by integrating radiomics, AI-supported diagnostics, and multimodal radiology to improve early disease detection, treatment response evaluation, and clinical decision-making. His contributions enhance patient safety, elevate diagnostic precision across oncology, cardiology, musculoskeletal, and infectious diseases, and support global healthcare innovation by translating advanced imaging technologies into practical, life-saving clinical applications.

Zixin Wang | Medicine | Best Researcher Award | 1743

Ms. Zixin Wang | Medicine | Best Researcher Award

Medical Student | Naval Medical University | China

Ms. Zixin Wang is an emerging researcher in the fields of tumor microenvironment biology and cancer immunotherapy, with a growing academic foundation in clinical medicine and surgical sciences. Her research interests are shaped by her training at the Second Military Medical University, where she pursued an undergraduate degree in Clinical Medicine (2021–2026), and her forthcoming academic engagement as a Master’s student in General Surgery at the Shanghai Medical College of Fudan University (2026–2029). Her academic trajectory reflects a strong commitment to translational oncology, integrating clinical insights with mechanistic research to improve therapeutic strategies for cancer patients. A key focus of Ms. Wang’s research is the tumor microenvironment (TME)—a complex cellular ecosystem that plays a decisive role in tumor progression, immune evasion, and treatment response. By studying the interactions between cancer cells, stromal components, and immune infiltrates, she aims to identify factors that influence immunotherapy effectiveness.Ms. Wang’s published work, “Mechanisms, advances, and challenges of immunotherapy in gastric cancer” in Frontiers in Immunology (2025), highlights her expertise in analyzing current and emerging immunotherapeutic modalities, including checkpoint inhibition, CAR-T cell therapy, and tumor vaccine development. Her scholarship examines both the molecular underpinnings and clinical bottlenecks of these therapies, with particular emphasis on the heterogeneity of gastric cancer, resistance pathways, and TME-driven immunosuppression.Through her interdisciplinary approach spanning clinical practice and immune-oncology research, Ms. Wang aims to contribute to the development of more precise, responsive, and personalized cancer treatments. Her evolving body of work positions her as a promising young scientist dedicated to advancing the future of surgical oncology and immunotherapeutic innovation.

Profiles: ORCID

Featured Publications

Wang, Z., & Wang, T. (2025). Mechanisms, advances, and challenges of immunotherapy in gastric cancer. Frontiers in Immunology, 16, Article 1639487.

Ms. Zixin Wang’s work advances the scientific understanding of the tumor microenvironment and improves the design of next-generation immunotherapies for gastric cancer, supporting the development of more precise and effective treatment strategies. Her research contributes to society by enabling earlier, more targeted, and less toxic cancer care, while also informing clinical innovation within the biomedical and healthcare industries. With a vision focused on translational impact, her efforts aim to accelerate global progress in cancer immunotherapy and personalized oncology.